

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2939821/publications.pdf>

Version: 2024-02-01

61  
papers

4,038  
citations

279701

23  
h-index

138417

58  
g-index

62  
all docs

62  
docs citations

62  
times ranked

3237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns and prognosis of regional recurrence in nasopharyngeal carcinoma after intensity-modulated radiotherapy. <i>Cancer Medicine</i> , 2023, 12, 1399-1408.	1.3	2
2	USP44 regulates irradiation-induced DNA double-strand break repair and suppresses tumorigenesis in nasopharyngeal carcinoma. <i>Nature Communications</i> , 2022, 13, 501.	5.8	32
3	Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials. <i>Radiation Oncology</i> , 2022, 17, 36.	1.2	2
4	Long-Term Evaluation and Normal Tissue Complication Probability (NTCP) Models for Predicting Radiation-Induced Optic Neuropathy after Intensity-Modulated Radiation Therapy (IMRT) for Nasopharyngeal Carcinoma: A Large Retrospective Study in China. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	1
5	The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , 2022, , .	1.3	3
6	Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization. <i>BMC Cancer</i> , 2022, 22, 353.	1.1	23
7	Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 46.	7.1	9
8	Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature. <i>Cancer Medicine</i> , 2022, 11, 4673-4687.	1.3	7
9	A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	31
10	A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 471-480.	3.0	17
11	Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. <i>Molecular Cancer</i> , 2021, 20, 14.	7.9	48
12	Evolving landscape and academic attitudes toward the controversies of global immuno-oncology trials. <i>International Journal of Cancer</i> , 2021, 149, 108-118.	2.3	5
13	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. <i>Molecular Cancer</i> , 2021, 20, 27.	7.9	54
14	Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth. <i>FASEB Journal</i> , 2021, 35, e21885.	0.2	4
15	The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. <i>Cancer Communications</i> , 2021, 41, 1195-1227.	3.7	128
16	<i>ZNF582</i> hypermethylation promotes metastasis of nasopharyngeal carcinoma by regulating the transcription of adhesion molecules <i>Nectin3</i> and <i>NRXN3</i> . <i>Cancer Communications</i> , 2020, 40, 721-737.	3.7	18
17	Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. <i>Cell Research</i> , 2020, 30, 1024-1042.	5.7	182
18	AR-induced long non-coding RNA LINC01503 facilitates proliferation and metastasis via the SFPQ-FOSL1 axis in nasopharyngeal carcinoma. <i>Oncogene</i> , 2020, 39, 5616-5632.	2.6	24

#	ARTICLE	IF	CITATIONS
19	Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology. , 2020, 8, e000334.		21
20	A Field Test of Major Value Frameworks in Chemotherapy of Nasopharyngeal Carcinomaâ€”To Know, Then to Measure. Frontiers in Oncology, 2020, 10, 1076.	1.3	1
21	Prognostic value of MRIâ€”determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Medicine, 2020, 9, 7100-7106.	1.3	11
22	Prognosis and staging of parotid lymph node metastasis in nasopharyngeal carcinoma: An analysis in 10,126 patients. Oral Oncology, 2019, 95, 150-156.	0.8	14
23	Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Communications, 2019, 39, 1-4.	3.7	21
24	Thyroid doseâ€”volume thresholds for the risk of radiationâ€”related hypothyroidism in nasopharyngeal carcinoma treated with intensityâ€”modulated radiotherapyâ€”A singleâ€”institution study. Cancer Medicine, 2019, 8, 6887-6893.	1.3	19
25	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine, 2019, 381, 1124-1135.	13.9	573
26	Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. Radiology, 2019, 291, 677-686.	3.6	221
27	The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensityâ€”modulated radiotherapy era. Cancer Medicine, 2019, 8, 2213-2222.	1.3	11
28	Patterns of EBV-positive cervical lymph node involvement in head and neck cancer and implications for the management of nasopharyngeal carcinoma T0 classification. Oral Oncology, 2019, 91, 7-12.	0.8	16
29	Evidence Underlying Recommendations and Payments from Industry to Authors of the National Comprehensive Cancer Network Guidelines. Oncologist, 2019, 24, 498-504.	1.9	7
30	Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. , 2019, 7, 298.		40
31	Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data. Frontiers in Oncology, 2019, 9, 1343.	1.3	24
32	Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Radiotherapy and Oncology, 2019, 132, 178-187.	0.3	24
33	Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort. Oral Oncology, 2019, 89, 102-106.	0.8	16
34	Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Longâ€”term results of phase 3 randomized controlled trial. International Journal of Cancer, 2019, 145, 295-305.	2.3	168
35	Proposed modifications and incorporation of plasma Epsteinâ€”Barr virus DNA improve the TNM staging system for Epsteinâ€”Barr virusâ€”related nasopharyngeal carcinoma. Cancer, 2019, 125, 79-89.	2.0	143
36	Spontaneous remission of residual postâ€”therapy plasma Epsteinâ€”Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A largeâ€”scale, bigâ€”data intelligence platformâ€”based analysis. International Journal of Cancer, 2019, 144, 2313-2319.	2.3	30

#	ARTICLE	IF	CITATIONS
37	Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. <i>Oral Oncology</i> , 2018, 78, 37-45.	0.8	20
38	Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Cancer Science</i> , 2018, 109, 1609-1616.	1.7	11
39	Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis. <i>Oral Oncology</i> , 2018, 79, 40-46.	0.8	28
40	Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis. <i>Radiotherapy and Oncology</i> , 2018, 129, 389-395.	0.3	43
41	A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2018, 86, 258-265.	0.8	6
42	Relationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation. <i>Cancer Medicine</i> , 2018, 7, 5988-5998.	1.3	18
43	Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A large-scale cohort study. <i>Cancer Science</i> , 2018, 109, 1909-1919.	1.7	22
44	The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. <i>PLoS ONE</i> , 2018, 13, e0196730.	1.1	21
45	Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. <i>European Journal of Cancer</i> , 2017, 75, 150-158.	1.3	115
46	Socioeconomic factors and survival in patients with non-metastatic head and neck squamous cell carcinoma. <i>Cancer Science</i> , 2017, 108, 1253-1262.	1.7	33
47	Impact of marital status at diagnosis on survival and its change over time between 1973 and 2012 in patients with nasopharyngeal carcinoma: a propensity score-matched analysis. <i>Cancer Medicine</i> , 2017, 6, 3040-3051.	1.3	26
48	Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2017, 75, 120-126.	0.8	12
49	A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy. <i>Oral Oncology</i> , 2017, 75, 89-94.	0.8	26
50	Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy. <i>Journal of Cancer</i> , 2017, 8, 371-377.	1.2	25
51	Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 Cases. <i>Journal of Cancer</i> , 2016, 7, 1353-1359.	1.2	12
52	Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. <i>Lancet Oncology</i> , The, 2016, 17, 1509-1520.	5.1	704
53	Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial. <i>Oncologist</i> , 2016, 21, 1369-1376.	1.9	50
54	Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 61, 120-128.	1.2	30

#	ARTICLE	IF	CITATIONS
55	Pregnancy associated nasopharyngeal carcinoma: A retrospective case-control analysis of maternal survival outcomes. <i>Radiotherapy and Oncology</i> , 2015, 116, 125-130.	0.3	8
56	Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. <i>Radiotherapy and Oncology</i> , 2015, 116, 167-173.	0.3	14
57	A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2015, 26, 205-211.	0.6	96
58	Is replacement of the supraclavicular fossa with the lower level classification based on magnetic resonance imaging beneficial in nasopharyngeal carcinoma?. <i>Radiotherapy and Oncology</i> , 2014, 113, 108-114.	0.3	26
59	Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 163-171.	5.1	468
60	Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. <i>Lancet Oncology</i> , The, 2012, 13, 633-641.	5.1	274
61	Disparities in positive results and dissemination of randomized controlled trials in immuno-oncology. <i>International Reviews of Immunology</i> , 0, , 1-10.	1.5	0